Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | AMY1A | P0DUB6 | 6/20 | 0.40 |
| ▸ | CDK4 | P11802 | 5/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.40 |
| ▸ | CCND1 | P24385 | 5/20 | 0.40 |
| ▸ | CDK2 | P24941 | 5/20 | 0.40 |
| ▸ | CCND3 | P30281 | 5/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 2/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13607761 | 0.84 | PDE5A (0.52) | AMY1APDE5APDGFRBPDGFRAGAA | |
| SCHEMBL4833945 | 0.83 | AURKA (0.41) | AMY1ACDK4CCNA2CCND1CDK2 | |
| SCHEMBL11006162 | 0.81 | CDK4 (0.43) | ESR1ESR2CDK4CCNA2CCND1 | |
| SCHEMBL4839499 | 0.81 | PTGES (0.39) | ESR1ESR2AMY1AJAK2 | |
| SCHEMBL10689035 | 0.79 | ESR1 (0.42) | ESR1ESR2AMY1ACDK4CCNA2 | |
| SCHEMBL4834872 | 0.78 | CYP1A1 (0.53) | TP53POLBMAPT | |
| Trifluoroacetic Acid SCHEMBL4843458 | 0.77 | PDE5A (0.43) | AMY1APDE5AFGFR1HDAC6 | |
| SCHEMBL4839487 | 0.76 | TBK1 (0.45) | CHEK1KDRPDGFRATP53MAPT | |
| SCHEMBL10675183 | 0.74 | PDE5A (0.51) | ESR1ESR2AMY1ACDK4CCNA2 | |
| SCHEMBL10676462 | 0.74 | PDE2A (0.50) | ESR1ESR2CDK4CCNA2CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410966-B2 | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261333-A1 | Use of and some novel imidazopyridines | ITK, CSNK1A1, RPS6KA1 | ESR1 2788/4885ESR2 1362/4885AMY1A 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.